<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054339</url>
  </required_header>
  <id_info>
    <org_study_id>AGTC-AAT-002</org_study_id>
    <secondary_id>2009‐014286‐20</secondary_id>
    <secondary_id>R01HL069877</secondary_id>
    <secondary_id>R01FD003896</secondary_id>
    <nct_id>NCT01054339</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency</brief_title>
  <official_title>A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients With Alpha-1 Antitrypsin Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Genetic Technologies Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Applied Genetic Technologies Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of a recombinant adeno-associated virus
      vector expressing alpha-1 antitrypsin in patients with alpha-1 antitrypsin deficiency. Three
      groups of three subjects each will receive the study drug by intramuscular injection, with
      progressively larger doses in the second and third groups.

      Funding Sources - FDA OOPD and NIH NHLBI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a non-randomized, open-label, multi-center, sequential, three-arm, Phase 2
      clinical trial evaluating the safety and efficacy of administration of a rAAV1-CB-hAAT vector
      administered by IM injection. Each participant will receive rAAV1-CB-hAAT on a single
      occasion. Three groups of three subjects each will receive rAAV1-CB-hAAT at dosage levels of
      6 x 10e11 vg/kg, 1.9 x 10e12 vg/kg or 6 x 10e12 vg/kg by IM injection. Subjects in group 1
      will receive a total of 10 IM injections distributed across a single muscle site, subjects in
      group 2 will receive a total of 32 IM injections distributed across three muscle sites, and
      subjects in group 3 will receive 100 IM injections distributed across 10 muscle sites. Each
      injection will be given in a volume of 1.35 mL, at the appropriate vector concentration to
      achieve the desired total vector dose, and the injection density at each administration site
      (nine IM injections per 4 cm2 skin surface area) will be the same as the injection density
      that was well tolerated in a previous Phase 1 clinical trial with rAAV1-CB-hAAT. Safety will
      be monitored by evaluation of adverse events, hematology and clinical chemistry parameters,
      histological examination of muscle biopsies, and measurement of serum antibodies to AAT.
      Efficacy will be measured by evaluation of serum concentrations of M-specific AAT and total
      AAT and serum AAT phenotype determined on isoelectric focusing gels. Additional information
      to be collected will include presence of the vector in blood or semen, changes in serum
      anti-AAV antibody titers, and changes in T cell responses to AAV and AAT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Grade 3 or 4 Adverse Events</measure>
    <time_frame>During 1 year after study agent administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum M-specific Alpha-1 Antitrypsin Concentration</measure>
    <time_frame>During months 6-12 after study agent adminsitration</time_frame>
    <description>The change in serum M-specific alpha-1 antitrypsin concentration was calculated as the difference between the mean values at the screening and baseline visits and the mean values at the 6, 9 and 12 month visits. The standard error of the difference was calculated as sqrt(s1^2/n1 + s2^2/n2, where s1 is the standard deviation of the baseline mean, s2 is the standard deviation of the month 6-12 mean, n1 is the number of baseline values and n2 is the number of month 6-12 values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Total Alpha-1 Antitrypsin Concentrations</measure>
    <time_frame>During months 6-12 after study agent adminstration</time_frame>
    <description>The change in serum total alpha-1 antitrypsin concentration was calculated as the difference between the mean values at the screening and baseline visits and the mean values at the 6, 9 and 12 month visits. The standard error of the difference was calculated as sqrt(s1^2/n1 + s2^2/n2, where s1 is the standard deviation of the baseline mean, s2 is the standard deviation of the month 6-12 mean, n1 is the number of baseline values and n2 is the number of month 6-12 values.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Alpha-1 Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rAAV1-CB-hAAT</intervention_name>
    <description>Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin</description>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Middle dose</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a diagnosis of AAT-deficiency, as defined by a serum AAT level of less than 11 µM
             and a phenotype or genotype either homozygous for PI*Z or compound heterozygous
             consisting of PI*Z and another allele known to be associated with disease

          2. Be at least 18 and not more than 75 years of age

          3. Have a FEV1 &gt;25% of predicted value (post bronchodilator)

          4. Weigh ≤ 90 kg

          5. Not receiving AAT augmentation therapy currently or with the past 3 months, and not
             planning to begin such therapy for at least 12 months after administration of
             rAAV1-CB-hAAT

          6. Be willing to discontinue aspirin, aspirin-containing products, and other drugs that
             may alter platelet function, 7 days prior to dosing, resuming no earlier than 24 hours
             after the dose has been administered

          7. Have acceptable laboratory parameters

          8. For females of childbearing potential:

               -  A negative pregnancy test (urine or serum) at screening and at baseline (within 2
                  days before administration of study agent)

               -  Agreement to consistently use barrier contraception (condoms, diaphragm or
                  cervical cap with spermicide) or another form of contraception (e.g. intrauterine
                  device or hormonal contraception) from the screening visit until 12 months after
                  administration of rAAV1-CB-hAAT, for sexual activity that could lead to pregnancy

          9. For males of reproductive potential, agreement to consistently use barrier
             contraception (condoms with spermicide) for 12 months after administration of
             rAAV1-CB-hAAT, for sexual activity that could lead to pregnancy,

         10. Provide signed informed consent before screening

        Exclusion Criteria:

          1. Prior receipt of any AAV gene therapy product

          2. Use of anticoagulants or anti-platelet agents within 7 days prior to study agent
             administration

          3. History of immune response to human AAT augmentation therapy as indicated by clinical
             history of an adverse immune response to infusion and/or decreased therapeutic effect
             in combination with documentation of serum anti-AAT antibodies

          4. Use of acute oral or intravenous antibiotic therapy for a respiratory infection within
             28 days prior to study agent administration (long-term maintenance or chronic
             suppressive oral antibiotics, and antibiotics for a non-respiratory indication, are
             allowed)

          5. Use of oral or systemic corticosteroids within 28 days prior to study agent
             administration

          6. Use of any investigational agent, or any immunosuppressive drug(s), within 3 months
             prior to enrollment

          7. For females of childbearing potential, a positive pregnancy test at screening or
             baseline (within 2 days before rAAV1-CB-hAAT administration)

          8. Females who are breast feeding

          9. Have a significant abnormal EKG finding at screening and/or cardiac disease (e.g.
             recent myocardial infarction or CHF) within past 6 months

         10. Have had pulmonary edema or a pulmonary embolism within the past 6 months

         11. Have a history of immunodeficiency or other medical condition which leads the
             investigator to believe that the participant cannot comply with the protocol
             requirements or that may place the participant at an unacceptable risk for
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terence R. Flotte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts Medical School, Worcester, MA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce C. Trapnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Children's Hospital Medical Center, Cincinnati, OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert A. Sandhaus, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health, Denver, CO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noel G. McElvaney, MB, BCh, BAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beaumont Hospital, Dublin, Ireland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>2</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://agtc.com</url>
    <description>Applied Genetic Technologies Corporation</description>
  </link>
  <reference>
    <citation>Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, Rouhani F, Conlon TJ, Calcedo R, Betts MR, Spencer C, Byrne BJ, Wilson JM, Flotte TR. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16363-8. doi: 10.1073/pnas.0904514106. Epub 2009 Aug 12. Erratum in: Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17606.</citation>
    <PMID>19706466</PMID>
  </reference>
  <results_reference>
    <citation>Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, Campbell-Thompson M, Yachnis AT, Sandhaus RA, McElvaney NG, Mueller C, Messina LM, Wilson JM, Brantly M, Knop DR, Ye GJ, Chulay JD. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther. 2011 Oct;22(10):1239-47. doi: 10.1089/hum.2011.053. Epub 2011 Aug 24.</citation>
    <PMID>21609134</PMID>
  </results_reference>
  <results_reference>
    <citation>Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, McElvaney NG, Messina L, Tang Q, Rouhani FN, Campbell-Thompson M, Fu AD, Yachnis A, Knop DR, Ye GJ, Brantly M, Calcedo R, Somanathan S, Richman LP, Vonderheide RH, Hulme MA, Brusko TM, Wilson JM, Flotte TR. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest. 2013 Dec;123(12):5310-8. doi: 10.1172/JCI70314. Epub 2013 Nov 15.</citation>
    <PMID>24231351</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>August 14, 2012</results_first_submitted>
  <results_first_submitted_qc>August 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2012</results_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alpha-1 antitrypsin deficiency</keyword>
  <keyword>Adeno-associated virus vector</keyword>
  <keyword>AAV</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Human gene transfer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from two clinical trial sites (University of Massachusetts Medical Center and Cincinatti Children's Hospital Medical Center).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose</title>
          <description>rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg administered as 10 IM injections in one arm</description>
        </group>
        <group group_id="P2">
          <title>Middle Dose</title>
          <description>rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg administered as 10 IM injections in one arm and 11 IM injections in each leg (total of 32 injections)</description>
        </group>
        <group group_id="P3">
          <title>High Dose</title>
          <description>rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg administered as 10 IM injections in each arm and 10 IM injections in each of four sites in each leg (total of 100 injections)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose</title>
          <description>rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg administered as 10 IM injections in one arm</description>
        </group>
        <group group_id="B2">
          <title>Middle Dose</title>
          <description>rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg administered as 10 IM injections in one arm and 11 IM injections in each leg (total of 32 injections)</description>
        </group>
        <group group_id="B3">
          <title>High Dose</title>
          <description>rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg administered as 10 IM injections in each arm and 10 IM injections in each of four sites in each leg (total of 100 injections)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="26.4"/>
                    <measurement group_id="B2" value="48.7" spread="9.3"/>
                    <measurement group_id="B3" value="54.3" spread="3.5"/>
                    <measurement group_id="B4" value="51.1" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alpha-1 antitrypsin phenotype</title>
          <description>Alpha-1 antitrypsin phenotype determined by isoelectric focusing gel electrophoresis</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ZZ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SZ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum total alpha-1 antitrypsin concentration</title>
          <description>Average of values at screening and baseline visits. Includes 1 phenotype SZ subject in low dose group.</description>
          <units>microMolar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.56" spread="2.00"/>
                    <measurement group_id="B2" value="3.54" spread="0.12"/>
                    <measurement group_id="B3" value="3.45" spread="0.19"/>
                    <measurement group_id="B4" value="4.31" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Grade 3 or 4 Adverse Events</title>
        <time_frame>During 1 year after study agent administration</time_frame>
        <population>Analysis based on all subjects enrolled in study.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg administered as 10 IM injections in one arm</description>
          </group>
          <group group_id="O2">
            <title>Middle Dose</title>
            <description>rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg administered as 10 IM injections in one arm and 11 IM injections in each leg (total of 32 injections)</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg administered as 10 IM injections in each arm and 10 IM injections in each of four sites in each leg (total of 100 injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Grade 3 or 4 Adverse Events</title>
          <population>Analysis based on all subjects enrolled in study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum M-specific Alpha-1 Antitrypsin Concentration</title>
        <description>The change in serum M-specific alpha-1 antitrypsin concentration was calculated as the difference between the mean values at the screening and baseline visits and the mean values at the 6, 9 and 12 month visits. The standard error of the difference was calculated as sqrt(s1^2/n1 + s2^2/n2, where s1 is the standard deviation of the baseline mean, s2 is the standard deviation of the month 6-12 mean, n1 is the number of baseline values and n2 is the number of month 6-12 values.</description>
        <time_frame>During months 6-12 after study agent adminsitration</time_frame>
        <population>One subject in low dose group had AAT phenotype SZ, which made measurement of M-specific serum alpha-1 antitrypsin concentration invalid.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg administered as 10 IM injections in one arm</description>
          </group>
          <group group_id="O2">
            <title>Middle Dose</title>
            <description>rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg administered as 10 IM injections in one arm and 11 IM injections in each leg (total of 32 injections)</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg administered as 10 IM injections in each arm and 10 IM injections in each of four sites in each leg (total of 100 injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum M-specific Alpha-1 Antitrypsin Concentration</title>
          <description>The change in serum M-specific alpha-1 antitrypsin concentration was calculated as the difference between the mean values at the screening and baseline visits and the mean values at the 6, 9 and 12 month visits. The standard error of the difference was calculated as sqrt(s1^2/n1 + s2^2/n2, where s1 is the standard deviation of the baseline mean, s2 is the standard deviation of the month 6-12 mean, n1 is the number of baseline values and n2 is the number of month 6-12 values.</description>
          <population>One subject in low dose group had AAT phenotype SZ, which made measurement of M-specific serum alpha-1 antitrypsin concentration invalid.</population>
          <units>nanomolar</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="7.56"/>
                    <measurement group_id="O2" value="71.8" spread="27.82"/>
                    <measurement group_id="O3" value="239.2" spread="33.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Total Alpha-1 Antitrypsin Concentrations</title>
        <description>The change in serum total alpha-1 antitrypsin concentration was calculated as the difference between the mean values at the screening and baseline visits and the mean values at the 6, 9 and 12 month visits. The standard error of the difference was calculated as sqrt(s1^2/n1 + s2^2/n2, where s1 is the standard deviation of the baseline mean, s2 is the standard deviation of the month 6-12 mean, n1 is the number of baseline values and n2 is the number of month 6-12 values.</description>
        <time_frame>During months 6-12 after study agent adminstration</time_frame>
        <population>Analysis bsed on all subjects enrolled in study.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg administered as 10 IM injections in one arm</description>
          </group>
          <group group_id="O2">
            <title>Middle Dose</title>
            <description>rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg administered as 10 IM injections in one arm and 11 IM injections in each leg (total of 32 injections)</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg administered as 10 IM injections in each arm and 10 IM injections in each of four sites in each leg (total of 100 injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Total Alpha-1 Antitrypsin Concentrations</title>
          <description>The change in serum total alpha-1 antitrypsin concentration was calculated as the difference between the mean values at the screening and baseline visits and the mean values at the 6, 9 and 12 month visits. The standard error of the difference was calculated as sqrt(s1^2/n1 + s2^2/n2, where s1 is the standard deviation of the baseline mean, s2 is the standard deviation of the month 6-12 mean, n1 is the number of baseline values and n2 is the number of month 6-12 values.</description>
          <population>Analysis bsed on all subjects enrolled in study.</population>
          <units>micromolar</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="1.14"/>
                    <measurement group_id="O2" value="0.16" spread="0.10"/>
                    <measurement group_id="O3" value="0.19" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose</title>
          <description>rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg administered as 10 IM injections in one arm</description>
        </group>
        <group group_id="E2">
          <title>Middle Dose</title>
          <description>rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg administered as 10 IM injections in one arm and 11 IM injections in each leg (total of 32 injections)</description>
        </group>
        <group group_id="E3">
          <title>High Dose</title>
          <description>rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg administered as 10 IM injections in each arm and 10 IM injections in each of four sites in each leg (total of 100 injections)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diverticulitis</sub_title>
                <description>A 51 y/o man received high dose of study drug on 5 Oct 2010, diverticulitis diagnosed on 14 Mar 2011, admitted to hospital, treated with antibiotics and symptoms resolved. The adverse event was considered not related to study agent.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <description>Because of small sample size, adverse events are listed only for (1) those considered possibly, probably or definitely related to study agent or study agent administration procedures, or (2) that occurred in more than 1 subject in the study.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Post-procedural discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>One other subject in the low dose group and one other subject in the mid dose group had blood CPK increase that was not considered an adverse event.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study results based on small number of subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey D. Chulay, MD</name_or_title>
      <organization>Applied Genetic Technologies Corp.</organization>
      <phone>386-462-2204 ext 205</phone>
      <email>jchulay@agtc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

